AGM Statement At an Annual General Meeting of Albion

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
57
AGM Statement

At an Annual General Meeting of Albion Venture Capital Trust PLC, duly convened and held at the City of London Club, 19 Old Broad Street, London on 13 August 2018 the following resolutions were passed:

Ordinary resolutions numbers 1 to 8 were passed. The following items of Special Business were passed of which resolutions 9 and 10 were passed as ordinary resolutions and 11 to 13 were passed as special resolutions.

Special Business
9.         Change of investment policy
That the Company’s current investment policy be replaced by the following:

The Company will invest in a broad portfolio of smaller, unquoted growth businesses across a variety of sectors including higher risk technology companies. Investments may take the form of equity or a mixture of equity and loans.

Allocation of funds will be determined by the investment opportunities which become available but efforts will be made to ensure that the portfolio is diversified both in terms of sector and stage of maturity of company. Funds held pending investment or for liquidity purposes will be held as cash on deposit.

Risk diversification and maximum exposures
Risk is spread by investing in a number of different businesses within venture capital trust qualifying industry sectors. The maximum amount which the Company will invest in a single portfolio company is 15 per cent. of the Company’s assets at cost, thus ensuring a spread of investment risk. The value of an individual investment may increase over time as a result of trading progress and it is possible that it may grow in value to a point where it represents a significantly higher proportion of total assets prior to a realisation opportunity being available.

Gearing
The Company’s maximum exposure in relation to gearing is restricted to 10 per cent. of the adjusted share capital and reserves.

10.       Authority to allot shares
That the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the “Act”) to allot shares of nominal value 1 penny per share in the Company up to an aggregate nominal amount of £192,486 representing approximately 20 per cent. of the total Ordinary share capital as at the date of the Notice, provided that this authority shall expire 15 months from the date that this resolution is passed, or at the conclusion of the next Annual General Meeting, whichever is earlier, but so that the Company may, before the expiry of such period, make an offer or agreement which would or might require shares to be allotted after the expiry of such period and the Directors may allot shares pursuant to such an offer or agreement as if the authority had not expired.

11. Authority for the disapplication of pre-emption rights
That the Directors be empowered, pursuant to section 570 of the Act, to allot equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authority conferred by resolution number 10 and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Act did not apply to any such allotment or sale.

Under this power the Directors may impose any limits or restrictions and make any arrangements which they deem necessary or expedient to deal with any treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or laws of, any territory or other matter, arising under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory or any other matter.
This power shall expire 15 months from the date that this resolution is passed or, if earlier, the conclusion of the next Annual General Meeting of the Company, save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if this power had not expired.

12. Authority to purchase own shares
That, subject to and in accordance with the Company’s Articles of Association, the Company be generally and unconditionally authorised, pursuant to and in accordance with section 701 of the Act, to make market purchases (within the meaning of Section 693(4) of the Act) of Ordinary shares of 1 penny each in the capital of the Company (“Ordinary shares”), on such terms as the Directors think fit provided that:

(a)        the maximum aggregate number of shares hereby authorised to be purchased is 14,426,856 shares representing 14.99 per cent. of the issued Ordinary share capital of the Company as at the date of this Notice;
(b)        the minimum price, exclusive of any expenses, which may be paid for an ordinary share is 1 penny;
(c)        the maximum price, exclusive of any expenses, which may be paid for a share shall be an amount equal to the higher of (a) 105% of the average of the middle market quotations for the share, as derived from the London Stock Exchange Daily Official List, for the five business days immediately preceding the date on which the share is purchased; and (b) the amount stipulated by Article 5(1) of the Buy-back and Stabilisation Regulation 2003;
(d)        the authority hereby conferred shall, unless previously revoked, varied or renewed, expire 15 months from the date that this resolution is passed or, if earlier, at the conclusion of the next Annual General Meeting; and
(e)        the Company may enter into a contract or contracts to purchase shares under this authority before the expiry of the authority which will or may be executed wholly or partly after the expiry of the authority, and may make a purchase of shares in pursuance of any such contract or contracts as if the authority conferred hereby had not expired.

13. Authority to sell treasury shares
That the Directors be empowered to sell treasury shares at the higher of the prevailing current share price and the price bought in at.

13 August 2018

For further information please contact:
Albion Capital Group LLP
Company Secretary
Tel: 0207 601 1850

LEI Code 213800JKELS32V2OK421

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 69

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading
China, Europe, Africa Team Up for Green Energy Push

Updated Category News Views 9

The Need for Unity in a Warming World Some folks out there might be scratching their heads, wondering what sparks are flying between China, Europe, and Africa this time. Well, during the 2026 China-Europe-Africa Green Energy Development Forum held in sunny Zhejiang, the theme was loud and clear: We've got to deepen green partnerships to build a zero-carbon future. They're...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 154

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
New Leadership at Reactive Tech: Claudio Facchin Steps In

Updated Category News Views 56

Facchin Joins Reactive Technologies: Power Play or Predictable Move? Let me tell you, the energy sector ain’t for the faint-hearted—especially when you’re talking grid stability. Reactive Technologies just tossed an ace on the table, appointing Claudio Facchin as the new Board Chairman. If you've been around the block, you might recognize Facchin's name from his...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 120

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Rosti Group Expands with Alvi Acquisition

Updated Category News Views 24

Rosti Bets on Expansion with Alvi Buyout Rosti Group just rolled the dice big by swallowing Alvi Group, marking another bold move in the ever-swinging industrial and medical device manufacturing rodeo. Suddenly, we’re talking about a company with roughly 3,000 employees on its roster and a neat EUR 450 million in combined revenue. Don't overlook the power play...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 93

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 247

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 513

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone

Updated Category News Views 91

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Continue Reading

Top 5 Most Recently Viewed Articles

Transformative Leadership: Jim Pendergast Joins Safe & Green Holdings

Updated Category News Views 432

Safe & Green Holdings Corp. Welcomes New COO, Jim Pendergast Safe & Green Holdings Corp. (NASDAQ: SGBX) is excited to announce the appointment of Jim Pendergast as the new Chief Operating Officer. This pivotal addition to the leadership team marks an important step forward in the company's vision of driving innovation and excellence in modular construction. Profile of Jim...

Continue Reading
Rosen Law Firm Investigates Claims for Mutual Fund Investors

Updated Category News Views 154

Understanding Rosen Law Firm's Investigation for Investors Rosen Law Firm is central to the ongoing concern surrounding mutual funds from Western Asset Management Company. We're here to guide investors in understanding their rights and possible claims associated with these investments. The Allegations Against Western Asset Management Company Recent allegations indicate...

Continue Reading
US Electronic Warfare Sector Set for Major Growth by 2028

Updated Category News Views 181

Projected Growth of the US Electronic Warfare Market The US Electronic Warfare market is on track to achieve a remarkable USD 8.99 billion by 2028, following a growth pattern from USD 6.45 billion in 2024, showcasing a compound annual growth rate (CAGR) of 8.6% during this period. The United States is globally acknowledged as a leading manufacturer and user of electronic...

Continue Reading
Ping An's New Shenzhen Hospital Redefines Rehabilitation Care

Updated Category News Views 162

Ping An Unveils Innovative Self-Operated Hospital in Shenzhen PING AN is excited to announce the opening of its latest self-operated hospital in Shenzhen, named Shenzhen Beiyi Rehabilitation Hospital. This facility represents a significant milestone in health and senior care, catering to the growing needs of residents in the Greater Bay Area. Commitment to Comprehensive...

Continue Reading
PARRIS Law Firm Triumphs in Landmark Billing Case Against Edison

Updated Category News Views 262

PARRIS Law Firm Achieves Major Victory in Consumer Lawsuit The PARRIS Law Firm has recently celebrated a significant win for consumers in a landmark lawsuit against Southern California Edison Company. This case, referencing the Wellman v. Southern California Edison Company, has captured media attention, notably from The Daily Journal, showcasing the firm’s commitment to...

Continue Reading